1. Home
  2. RNST vs EVO Comparison

RNST vs EVO Comparison

Compare RNST & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNST

Renasant Corporation

HOLD

Current Price

$39.28

Market Cap

3.6B

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$1.62

Market Cap

568.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNST
EVO
Founded
1904
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
568.6M
IPO Year
1997
2007

Fundamental Metrics

Financial Performance
Metric
RNST
EVO
Price
$39.28
$1.62
Analyst Decision
Buy
Buy
Analyst Count
7
3
Target Price
★ $48.14
$4.17
AVG Volume (30 Days)
★ 597.0K
159.1K
Earning Date
10-27-2026
11-05-2026
Dividend Yield
★ 2.42%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 1.88
N/A
Revenue
N/A
N/A
Revenue This Year
$12.20
N/A
Revenue Next Year
$3.25
$20.51
P/E Ratio
$21.08
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.04
$1.50
52 Week High
$44.54
$4.27

Technical Indicators

Market Signals
Indicator
RNST
EVO
Relative Strength Index (RSI) 39.37 41.31
Support Level $39.11 $1.50
Resistance Level $40.84 $1.97
Average True Range (ATR) 0.75 0.07
MACD -0.01 0.02
Stochastic Oscillator 42.67 46.00

Price Performance

Historical Comparison
RNST
EVO

About RNST Renasant Corporation

Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has two reportable segments: Community banks and Wealth management. With its Community Banks segment, the company provides a range of financial services to individuals and small businesses. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: